{"gene":"DCLK1","run_date":"2026-06-09T23:54:41","timeline":{"discoveries":[{"year":2000,"finding":"DCAMKL1/DCLK1 protein associates with microtubules and stimulates polymerization of purified tubulin, forming aster-like microtubule structures. Overexpressed DCAMKL1 causes striking microtubule bundling in cell lines and primary neural cells. DCAMKL1 also encodes a functional kinase capable of phosphorylating myelin basic protein and itself (autophosphorylation). Elimination of kinase activity has no detectable effect on microtubule polymerization activity, indicating these two functions are separable.","method":"In vitro microtubule polymerization assay with purified protein; overexpression in cell lines; kinase activity assay with MBP substrate; kinase-dead mutagenesis; time-lapse live-cell imaging of GFP-fusion","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with purified protein, mutagenesis separating kinase from MAP function, multiple orthogonal methods in one rigorous study","pmids":["11124993"],"is_preprint":false},{"year":2016,"finding":"DCLK1 labels a subset of dendritic microtubules and is required for kinesin-3 (KIF1)-dependent dense-core vesicle trafficking into dendrites and for dendrite development. Screening of all 45 kinesin family members identified KIF1/kinesin-3 and KIF21/kinesin-4 subfamily members as capable of dendritic transport; DCLK1 on dendritic microtubules provides local signals directing KIF1-dependent cargo specifically to dendrites.","method":"Kinesin family-wide screen in living cells; live imaging of cargo transport in hippocampal neurons; DCLK1 knockdown with phenotypic readout (DCV trafficking, dendrite development)","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — systematic screen plus KD with specific cellular phenotype, multiple orthogonal methods, single rigorous study","pmids":["26758546"],"is_preprint":false},{"year":2016,"finding":"DCLK1 phosphorylates MAP7D1 (microtubule-associated protein 7 domain containing 1) at serine 315 to promote axon elongation of cortical neurons. MAP7D1 was identified as a DCLK1 substrate by proteomic analysis; knockdown of MAP7D1 impairs callosal axon elongation but not radial migration. Overexpression of phosphomimetic MAP7D1-S315E fully rescues axon elongation defects in Dclk1-knockdown neurons, whereas wild-type MAP7D1 does not.","method":"Phosphoproteomics/proteomic substrate identification; shRNA knockdown in cortical neurons; in utero electroporation; phosphomimetic rescue experiment","journal":"Developmental neurobiology","confidence":"High","confidence_rationale":"Tier 1 / Strong — substrate identified by proteomics, phosphorylation site defined, phosphomimetic rescue validates functional relevance, multiple orthogonal methods","pmids":["27503845"],"is_preprint":false},{"year":2021,"finding":"DCLK1 kinase domain adopts an autoinhibited state in which the C-terminal autoinhibitory domain (AID) blocks the ATP-binding site competitively with ATP. The neuronal calcium sensor HPCAL1 binds directly to the AID in a Ca²⁺-dependent manner, releasing autoinhibition and activating DCLK1 kinase activity. Cancer-associated mutations in the AID disrupt autoinhibition to upregulate kinase activity.","method":"Crystal structure of DCLK1 kinase domain in autoinhibited state; biochemical binding assays (HPCAL1–AID interaction); Ca²⁺-dependent activation assay; analysis of cancer-associated AID mutations","journal":"Innovation (Cambridge (Mass.))","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus biochemical validation of activator binding and mutational analysis, multiple orthogonal methods in one study","pmids":["34977835"],"is_preprint":false},{"year":2021,"finding":"Crystal structures of the DCLK1 kinase domain in complex with selective inhibitor DCLK1-IN-1 and its precursors were determined, revealing that DCLK1-IN-1 induces a drastic conformational change of the ATP binding site explaining its high selectivity. DCLK1-IN-1 binds DCLK1 long isoforms but does not prevent DCLK1's microtubule-associated protein (MAP) function.","method":"X-ray crystallography of kinase domain–inhibitor co-crystals; structure-activity relationship analysis; functional assay distinguishing kinase vs. MAP activity","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structures with SAR validation and functional dissection of MAP vs. kinase activity","pmids":["34545159"],"is_preprint":false},{"year":2020,"finding":"Using a DCLK1 chemical biology toolkit (inhibitor DCLK1-IN-1, inhibitor-resistant G532A mutant, kinase-dead D511N and D533N mutants), DCLK1 kinase activity was linked to RNA processing. Phosphoproteomics identified CDK11 as a potential substrate of DCLK1 kinase activity.","method":"Pharmacological inhibition with DCLK1-IN-1; engineered inhibitor-resistant and kinase-dead cell lines; phosphoproteomics","journal":"Cell chemical biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — phosphoproteomics with genetic controls (resistant mutant, kinase-dead), single lab, substrate identification is preliminary","pmids":["32755567"],"is_preprint":false},{"year":2004,"finding":"Two DCLK-short splice variants (DCLK-short-A and -B) both phosphorylate autocamtide and syntide (CaMK-specific substrates), confirming kinase activity. Removal of the C-terminal end of DCLK-short produces a ~10-fold increase in kinase activity, demonstrating that distinct C-termini function as autoinhibitory domains. The two variants localize differently: both are cytoplasmic, but DCLK-short-B also localizes to growth-cone-like structures and near the nucleus.","method":"In vitro kinase assay with CaMK substrates; C-terminal truncation mutagenesis; immunofluorescence localization in cells","journal":"Brain research. Molecular brain research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro kinase assay with mutagenesis demonstrating autoinhibitory domain, combined with localization data","pmids":["14741399"],"is_preprint":false},{"year":2013,"finding":"DCAMKL1 represses osteoblast differentiation/activation by antagonizing Runx2, the master transcription factor of osteoblasts. Dcamkl1-null mice display elevated bone mass secondary to increased bone formation by osteoblasts. Genetic epistasis showed that key elements of the cleidocranial dysplasia phenotype in Runx2+/- mice are reversed by introduction of a Dcamkl1-null allele, establishing in vivo genetic linkage between DCAMKL1 and Runx2.","method":"Targeted gene disruption (Dcamkl1-null mice); shRNA screen (forward genetic); bone mass phenotyping; Runx2+/-;Dcamkl1-/- double-mutant epistasis","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis with double-mutant in vivo rescue, multiple orthogonal methods, defines mechanistic pathway position","pmids":["23918955"],"is_preprint":false},{"year":2023,"finding":"Macrophage DCLK1 promotes atherosclerosis by directly interacting with IKKβ and phosphorylating IKKβ at S177/181, thereby facilitating NF-κB activation and inflammatory gene expression. Coimmunoprecipitation followed by LC-MS/MS identified IKKβ as a DCLK1-binding protein; macrophage-specific DCLK1 deletion attenuates atherosclerosis in ApoE-/- mice.","method":"Co-immunoprecipitation + LC-MS/MS; in vitro kinase assay on IKKβ; macrophage-specific conditional knockout mice; pharmacological DCLK1 inhibition in vivo","journal":"EMBO molecular medicine","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — substrate/binding partner identified by Co-IP+MS, kinase activity on IKKβ demonstrated, validated with macrophage-specific KO and pharmacological inhibition","pmids":["36896602"],"is_preprint":false},{"year":2023,"finding":"Macrophage-specific DCLK1 knockout (but not cardiomyocyte-specific knockout) prevents high-fat diet-induced cardiac dysfunction, hypertrophy, and fibrosis. DCLK1 mediates RIP2/TAK1 phosphorylation and subsequent inflammatory cytokine release in macrophages exposed to palmitate/HFD, which promotes hypertrophy in cardiomyocytes and fibrosis in fibroblasts.","method":"Cell-type-specific conditional knockout mice; RNA sequencing; in vitro macrophage-cardiomyocyte/fibroblast co-culture; pharmacological DCLK1 inhibition in vivo","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-type-specific KO with defined phenotype and RNA-seq, single lab","pmids":["37443105"],"is_preprint":false},{"year":2009,"finding":"DCAMKL-1 is a negative regulator of let-7a miRNA biogenesis in intestinal stem and colorectal cancer cells. siRNA-mediated knockdown of DCAMKL-1 in colon cancer cells and xenografts results in increased pri-let-7a miRNA, decreased luciferase activity from a let-7a reporter, and decreased c-Myc expression. DCAMKL-1+ cells isolated by FACS have significantly lower pri-let-7a compared with more differentiated cells.","method":"siRNA knockdown; luciferase reporter assay for let-7a; FACS isolation of DCAMKL-1+ cells; tumor xenograft growth assay; real-time RT-PCR","journal":"Gastroenterology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA KD with multiple readouts (luciferase reporter + endogenous target + xenograft), single lab","pmids":["19445940"],"is_preprint":false},{"year":2011,"finding":"DCAMKL-1 knockdown in human pancreatic cancer cells induces miR-200a (an EMT inhibitor), with downregulation of EMT transcription factors ZEB1, ZEB2, Snail, Slug, and Twist. Additionally, DCAMKL-1 knockdown downregulates c-Myc and KRAS through a let-7a-dependent mechanism and downregulates Notch-1 through a miR-144-dependent mechanism, establishing DCAMKL-1 as a regulator of multiple miRNA-dependent pathways controlling EMT.","method":"siRNA knockdown in pancreatic cancer cells; miRNA quantification by RT-PCR; immunoblot for downstream targets; KRAS transgenic mouse model colocalization","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA with multiple downstream pathway readouts, single lab","pmids":["21285251"],"is_preprint":false},{"year":2013,"finding":"DCLK1 knockdown using nanoparticle-encapsulated siRNA in pancreatic xenografts results in increased miR-145, leading to decreased pluripotency factors OCT4, SOX2, NANOG, KLF4, KRAS, and RREB1; increased let-7a, decreasing LIN28B; and increased miR-200, decreasing VEGFR1, VEGFR2, and EMT transcription factors. Luciferase-based reporter assays confirmed DCLK1-dependent post-transcriptional regulation of miR-145, miR-200, and let-7a downstream targets.","method":"siRNA nanoparticle delivery in xenograft model; luciferase reporter assay; immunoblot; RT-PCR","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays confirm direct regulation, in vivo xenograft validation, single lab","pmids":["24040120"],"is_preprint":false},{"year":2018,"finding":"DCLK1 induces NF-κBp65 subunit expression through the PI3K/Akt/Sp1 axis and activates NF-κBp65 through the PI3K/Akt/IκBα pathway during EMT in colorectal cancer cells. Silencing DCLK1 inhibits invasion and metastasis in vivo.","method":"siRNA knockdown; pharmacological pathway inhibitors; immunoblot for pathway components; in vivo xenograft invasion assay","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KD with pharmacological pathway dissection and in vivo validation, single lab","pmids":["29277893"],"is_preprint":false},{"year":2018,"finding":"Dclk1 expression in tuft cells is important for inflammation-induced COX2 expression and prostaglandin E2 (PGE2) production in vivo. Loss of Dclk1 in intestinal epithelial cells impairs inflammation-induced proliferative response of colonic organoids, and exogenous PGE2 rescues proliferative defects in Dclk1-deficient organoids. Dclk1 is required for Dclk1-ATM interaction and COX2 activation in response to injury.","method":"Conditional intestinal epithelial Dclk1 knockout mice; organoid culture; PGE2 rescue experiment; immunostaining; qPCR","journal":"Cell death and differentiation","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with organoid rescue experiment, specific molecular mechanism (COX2/PGE2), single lab","pmids":["30478383"],"is_preprint":false},{"year":2016,"finding":"Dclk1 expressed in tuft cells regulates ATM-mediated DNA damage response following radiation injury. Isolated intestinal epithelial cells from VillinCre;Dclk1f/f mice showed reduced injury-induced ATM and COX2 activation, reduced pro-survival gene expression, and reduced self-renewal ability. Interaction with Dclk1 is critical for ATM activation. Dclk1+ tuft cells regulate the broader intestinal epithelium through a paracrine mechanism.","method":"Conditional intestinal epithelial Dclk1 knockout mice; total body irradiation; ATM pathway assessment by immunoblot; self-renewal assay; co-IP for Dclk1-ATM interaction","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with defined molecular pathway phenotype and Co-IP interaction data, single lab","pmids":["27876863"],"is_preprint":false},{"year":2019,"finding":"DCLK1 overexpression in pancreatic cancer cells drives >2-fold increase in invasion and drug resistance and increases KRAS activation, as measured by a RAS pull-down assay. Co-immunoprecipitation demonstrated DCLK1–KRAS interaction. High DCLK1 expression in TCGA PAAD correlates with activated PI3K/AKT/MTOR pathway signaling consistent with elevated KRAS activity.","method":"Stable lentiviral DCLK1-isoform2 overexpression; Matrigel invasion assay; RAS activation pull-down assay; co-immunoprecipitation; Everolimus/LY294002/ABT-199 drug resistance assays; KPC mouse model","journal":"Journal of oncology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KRAS activation pull-down + Co-IP, overexpression gain-of-function with multiple readouts, single lab","pmids":["31467540"],"is_preprint":false},{"year":2022,"finding":"DCLK1 binds and phosphorylates XRCC5 (Ku80), which in turn transcriptionally activates cyclooxygenase-2 (COX-2) expression and enhances prostaglandin E2 (PGE2) production, generating an inflammatory tumor microenvironment and driving aggressive behavior of colorectal cancer cells. This mechanism was identified by comprehensive proteomics/genomics analysis and validated functionally in CRC mouse models.","method":"Proteomics and genomics analyses to identify DCLK1 binding partners; Co-IP for DCLK1–XRCC5 interaction; in vitro kinase assay; COX-2/PGE2 functional measurements; CRC mouse models","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — substrate identified by proteomics and Co-IP, kinase activity on XRCC5, in vivo validation, single lab","pmids":["35910805"],"is_preprint":false},{"year":2020,"finding":"DCLK1 influences small extracellular vesicle (sEV/exosome) biogenesis and cargo selection in a kinase-dependent manner in gastric cancer cells. sEVs from DCLK1-overexpressing cells promote migration of parental cells. Quantitative proteomics of sEVs identified enrichment of migratory/adhesion regulators (STRAP, CORO1B, BCAM, COL3A, CCN1). Treatment with DCLK1-IN-1 reversed increases in sEV size/concentration and kinase-dependent cargo selection of EV biogenesis proteins (KTN1, CHMP1A, MYO1G) and migration proteins.","method":"Stable DCLK1 overexpression; sEV isolation; quantitative proteomics of sEVs; DCLK1-IN-1 pharmacological inhibition; migration assay","journal":"Proteomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative proteomics with pharmacological kinase inhibition validation, single lab","pmids":["33991177"],"is_preprint":false},{"year":2019,"finding":"KDM3A histone demethylase binds to the DCLK1 promoter and increases DCLK1 expression by removing H3K9me2 methylation marks. Knockdown of KDM3A in pancreatic cancer cells reduces DCLK1 levels; overexpression of KDM3A in non-cancerous HPNE cells increases DCLK1. This epigenetic regulation was confirmed by ChIP assay identifying KDM3A binding sites in the DCLK1 promoter.","method":"KDM3A knockdown and overexpression in pancreatic cell lines; ChIP assay for KDM3A binding at DCLK1 promoter; RNA sequencing; immunofluorescence co-localization; orthotopic tumor models","journal":"Gastroenterology","confidence":"High","confidence_rationale":"Tier 2 / Strong — ChIP identifies KDM3A binding at DCLK1 promoter, loss- and gain-of-function experiments, in vivo validation, multiple orthogonal methods","pmids":["31442435"],"is_preprint":false},{"year":2015,"finding":"Human colorectal cancers predominantly express a short DCLK1 isoform (DCLK1-S) from an alternate β-promoter located in Intron V of the DCLK1 gene, while normal colons express DCLK1-L from the 5'(α)-promoter. Activated NF-κBp65 binding to NF-κB cis-elements activates the β-promoter in cancer cells, whereas β-catenin/TCF4/LEF binding sites activate the α-promoter. This was confirmed by promoter-reporter and molecular biology approaches.","method":"In silico promoter analysis; promoter-reporter assays; molecular biology characterization of isoforms; NF-κBp65 and β-catenin functional studies; cohort analysis of isoform expression","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assays with defined transcription factor binding sites, multiple molecular biology methods, single lab","pmids":["26447334"],"is_preprint":false},{"year":2018,"finding":"LEF1 (lymphoid enhancer-binding factor 1) directly binds the DCLK1-B promoter to transcriptionally activate DCLK1-B expression. Niclosamide blocks this interaction, reducing DCLK1-B expression. DCLK1-B depletion impairs cancer stemness, reduces survival, and sensitizes CRC to chemoradiation.","method":"Chromatin immunoprecipitation; promoter-reporter assays; siRNA knockdown of LEF1 and DCLK1-B; in vivo xenograft and AOM/DSS models","journal":"Clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP and reporter assay demonstrate LEF1 binding to DCLK1-B promoter, loss-of-function phenotype in vivo, single lab","pmids":["30446587"],"is_preprint":false},{"year":2021,"finding":"miR-195 directly interacts with the Dclk1 mRNA 3'-UTR and inhibits DCLK1 translation. RNA-binding protein HuR competes with miR-195 for binding to Dclk1 mRNA and increases DCLK1 expression. Transgenic miR-195 overexpression in mice reduces DCLK1-positive tuft cells and increases vulnerability of the gut barrier.","method":"Luciferase reporter assay with Dclk1 3'-UTR; intestinal epithelial miR-195 transgenic mice; organoid culture; RNA pulldown/RIP for HuR-Dclk1 mRNA interaction","journal":"American journal of physiology. Cell physiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — luciferase 3'-UTR reporter validates direct miR-195 targeting, HuR competition validated, transgenic mouse phenotype confirms functional relevance, single lab","pmids":["33788631"],"is_preprint":false},{"year":2022,"finding":"DCLK1 promotes immune escape in colorectal cancer by upregulating CXCL1, which recruits MDSCs through CXCR2 to suppress CD8+ T cell activity. DCLK1-/- tumor cells (CRISPR/Cas9) lose tumorigenicity under immune surveillance. Overexpression of CXCL1 rescued in vivo tumor growth of DCLK1-/- cells.","method":"CRISPR/Cas9 DCLK1 knockout tumor cells; subcutaneous and orthotopic tumor transplant models; flow cytometry of tumor-infiltrating immune cells; MDSC sorting and T-cell co-culture; RNA sequencing; CXCL1 rescue experiment","journal":"Cellular and molecular gastroenterology and hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — CRISPR KO with in vivo rescue experiment, MDSC mechanistic pathway validated by sorting/co-culture, RNA-seq, multiple orthogonal methods","pmids":["36309200"],"is_preprint":false},{"year":2016,"finding":"Dclk1+ cells are necessary for pancreatic regeneration following injury. In vivo, loss of Dclk1+ cells has detrimental effects after cerulein-induced pancreatitis. In vitro, Dclk1+ cells proliferate readily and sustain pancreatic organoid growth. In the context of oncogenic Kras, experimental pancreatitis converts Kras-mutant Dclk1+ cells into potent cancer-initiating cells.","method":"Genetic lineage tracing (Dclk1-CreER); cerulein-induced pancreatitis model; Dclk1+ cell ablation; in vitro organoid growth assay; Kras mutant mouse model","journal":"Cell stem cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic lineage tracing plus conditional cell ablation with defined regenerative and oncogenic phenotypes, multiple orthogonal in vivo and in vitro methods","pmids":["27058937"],"is_preprint":false},{"year":2012,"finding":"Dclk1 marks tumor stem cells (TSCs) rather than normal stem cells in the intestine of ApcMin/+ mice. Lineage tracing showed that Dclk1+ cells continuously produce tumor progeny in polyps. Specific ablation of Dclk1-positive TSCs resulted in marked regression of polyps without apparent damage to the normal intestine.","method":"Genetic lineage tracing (Dclk1-CreER;Rosa26-reporter); Dclk1+ cell-specific ablation in ApcMin/+ mice; polyp quantification; histological analysis of normal intestine","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — lineage tracing plus conditional cell ablation in genetic cancer model, clear TSC-specific vs. normal stem cell distinction established in vivo","pmids":["23202126"],"is_preprint":false},{"year":2014,"finding":"Dclk1 deletion in intestinal epithelial cells (VillinCre;Dclk1flox/flox) results in failure to maintain tight junctions after radiation injury and early lethality (~day 5 vs. day 10 in controls), demonstrating a functional role for Dclk1 in epithelial restoration after genotoxic insult. Widespread gene expression changes were detected in isolated intestinal epithelia during homeostasis in Dclk1-deficient mice.","method":"Conditional intestinal Dclk1 knockout mice; total body irradiation; survival analysis; tight junction assessment; global gene expression profiling","journal":"Stem cells (Dayton, Ohio)","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with specific phenotypic readout (tight junctions, survival), single lab","pmids":["24123696"],"is_preprint":false},{"year":2016,"finding":"DCLK1 overexpression in pancreatic neuroendocrine tumor (PNET) cells induces EMT-related gene signatures including upregulation of Slug/SNAI2, N-Cadherin, and Vimentin. QGP1-DCLK1 cells showed increased migration, formed larger xenograft tumors, and activated p-FAK (Tyr925), p-ERK1/2, p-AKT, Paxillin, and Cyclin D1. Pharmacological inhibition or knockdown of DCLK1 abolished expression of these molecules.","method":"DCLK1 overexpression in QGP1 cells; xenograft tumor model; wound-healing migration assay; immunoblot for FAK/ERK/AKT; pharmacological and siRNA inhibition","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function overexpression with pharmacological and siRNA inhibition confirming pathway activation, in vivo validation, single lab","pmids":["28179411"],"is_preprint":false},{"year":2022,"finding":"Thrombin activates DCLK1, which then activates RhoA and YAP in lung epithelial cells. YAP undergoes dephosphorylation at Ser127 and translocates to the nucleus. YAP and p65 are recruited to the NF-κB site of the IL-8/CXCL8 promoter, enhancing IL-8 expression. DCLK1 siRNA inhibited RhoA and YAP activation and blocked YAP/p65 recruitment to the IL-8 promoter. DCLK1/RhoA/YAP activation was ERK-dependent (inhibited by U0126).","method":"siRNA knockdown of DCLK1/RhoA/YAP; DCLK1 inhibitor LRRK2-IN-1; κB-luciferase reporter assay; ChIP assay for YAP/p65 at IL-8 promoter; Western blot for pathway components; in vivo asthma model","journal":"Journal of biomedical science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP validates pathway mechanism, multiple siRNA targets, luciferase reporter, single lab","pmids":["36369000"],"is_preprint":false},{"year":2022,"finding":"DCLK1 interacts with CCAR1 (cell cycle and apoptosis regulator 1) through its C-terminal domain and phosphorylates CCAR1 at Ser343, which is essential for CCAR1 stabilization. DCLK1 positively regulates β-catenin signaling via CCAR1, which maintains cancer stemness and 5-FU resistance in colorectal cancer cells.","method":"Co-immunoprecipitation for DCLK1–CCAR1 interaction; in vitro kinase assay for CCAR1 phosphorylation at Ser343; DCLK1/CCAR1 siRNA knockdown; β-catenin pathway analysis; 5-FU resistant cell line models; in vivo xenograft assay","journal":"Clinical and translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identifies binding partner, kinase assay demonstrates phosphorylation at specific site, downstream pathway validated, single lab","pmids":["35522902"],"is_preprint":false},{"year":2017,"finding":"Knockdown of Dclk1 in ApcMin/+ mice attenuates intestinal adenomas and adenocarcinoma, decreases pro-survival signaling (including NF-κB/RELA and NOTCH1 pathways), reduces pluripotency factors, and impairs self-renewal. Knocking down RELA, NOTCH1 signaling, and DCLK1 in colon cancer cells in vitro reduces tumor cell self-renewal and survival, establishing Dclk1 as a regulator of pro-survival and stemness signaling in intestinal tumors.","method":"Dclk1 knockdown in ApcMin/+ mice; siRNA knockdown of RELA and NOTCH1 in colon cancer cells; FACS; IHC; Western blot; clonogenic self-renewal assays","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KD with pathway-specific siRNA epistasis in vitro, multiple readouts, single lab","pmids":["28148261"],"is_preprint":false},{"year":2020,"finding":"DCLK1-isoform2 overexpression in pancreatic cancer cells causes polarization of M1-macrophages toward an immunosuppressive M2 phenotype via secreted chemokines/cytokines. DCLK1-isoform2-educated M2-macrophages enhance parental PDAC cell migration, invasion, and self-renewal, and inhibit CD8+ T-cell proliferation and granzyme-B activation. Inhibition of DCLK1 in an organoid co-culture system enhanced CD8+ T-cell activation and organoid death.","method":"DCLK1-isoform2 stable overexpression; macrophage polarization assay; CD8+ T-cell co-culture; organoid co-culture with DCLK1 inhibition; KPCY autochthonous mouse model immunostaining","journal":"Molecular cancer therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with macrophage co-culture and T-cell functional assays, in vivo mouse model validation, single lab","pmids":["32371580"],"is_preprint":false},{"year":2019,"finding":"DCLK1 overexpression promotes EMT and activates the ERK MAPK pathway in breast cancer cells, leading to enhanced expression of MT1-MMP. CRISPR/Cas9-mediated DCLK1 knockout reduces EMT markers (decreases ZO-1 loss, reduces ZEB1 and Vimentin), and reduces migration and invasion. This identifies ERK MAPK/MT1-MMP as a downstream pathway of DCLK1 in breast cancer metastasis.","method":"CRISPR/Cas9 DCLK1 knockout; stable DCLK1 overexpression; migration/invasion assays; immunoblot for EMT and ERK MAPK pathway markers; MT1-MMP expression analysis","journal":"BioMed research international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR KO plus overexpression with pathway analysis, single lab","pmids":["31223610"],"is_preprint":false}],"current_model":"DCLK1 is a bifunctional microtubule-associated serine/threonine kinase: its N-terminal doublecortin-like domain binds and polymerizes microtubules (independent of kinase activity), while its C-terminal kinase domain—held in autoinhibition by a C-terminal autoinhibitory domain (AID) that blocks the ATP-binding site—is activated by Ca²⁺-dependent binding of HPCAL1 to the AID; in neurons DCLK1 phosphorylates MAP7D1-Ser315 to promote axon elongation and labels dendritic microtubules to guide KIF1-dependent cargo trafficking; in cancer cells DCLK1 kinase activity drives EMT and stemness via multiple miRNA-dependent (let-7a, miR-200, miR-145) and kinase-dependent mechanisms including phosphorylation of IKKβ-S177/181 (activating NF-κB in macrophages), XRCC5/Ku80 (activating COX-2/PGE2), and CCAR1-Ser343 (stabilizing β-catenin signaling), and promotes immune evasion through CXCL1-mediated MDSC recruitment and M2 macrophage polarization; DCLK1 expression is epigenetically regulated by KDM3A-mediated H3K9 demethylation and by NF-κB-driven alternate promoter usage in cancer cells."},"narrative":{"mechanistic_narrative":"DCLK1 is a bifunctional microtubule-associated serine/threonine kinase whose two activities are structurally and functionally separable: an N-terminal doublecortin-like domain binds purified tubulin and drives microtubule polymerization and bundling independent of catalytic activity, while a distinct C-terminal kinase domain phosphorylates protein substrates [PMID:11124993]. The kinase domain is held in an autoinhibited conformation by a C-terminal autoinhibitory domain (AID) that occludes the ATP-binding site; truncation of the C-terminus elevates activity ~10-fold, and Ca²⁺-dependent binding of the neuronal calcium sensor HPCAL1 to the AID releases this autoinhibition, while cancer-associated AID mutations constitutively upregulate kinase activity [PMID:34977835, PMID:14741399]. In the nervous system DCLK1 decorates a subset of dendritic microtubules to direct KIF1/kinesin-3-dependent dense-core vesicle trafficking and dendrite development, and phosphorylates MAP7D1 at Ser315 to promote cortical axon elongation [PMID:26758546, PMID:27503845]. Beyond neurons, DCLK1 marks regenerative and tumor-initiating cell populations: Dclk1+ tuft/stem cells support intestinal and pancreatic epithelial restoration after injury and, in oncogenic Kras or Apc-mutant contexts, behave as cancer-initiating/tumor stem cells whose ablation regresses tumors without harming normal tissue [PMID:27058937, PMID:23202126, PMID:30478383]. In cancer its kinase activity drives EMT, stemness, and an inflammatory microenvironment through defined substrates and partners—phosphorylating IKKβ at S177/181 to activate NF-κB in macrophages [PMID:36896602], XRCC5/Ku80 to transcriptionally induce COX-2/PGE2 [PMID:35910805], and CCAR1 at Ser343 to stabilize β-catenin signaling [PMID:35522902]—and through repression of tumor-suppressive miRNA programs (let-7a, miR-200, miR-145) that control pluripotency factors, KRAS, and EMT transcription factors [PMID:19445940, PMID:21285251, PMID:24040120]. DCLK1 further promotes immune evasion via CXCL1-driven MDSC recruitment and M2 macrophage polarization [PMID:36309200, PMID:32371580]. DCLK1 expression itself is controlled epigenetically by KDM3A-mediated H3K9 demethylation at its promoter and by a switch to an alternate NF-κB/LEF1-driven β-promoter producing a short isoform in cancer [PMID:31442435, PMID:26447334, PMID:30446587].","teleology":[{"year":2000,"claim":"Established that DCLK1 is a dual-function protein—a microtubule-polymerizing MAP and an active kinase—whose two activities are genetically separable, framing all later mechanistic work.","evidence":"In vitro microtubule polymerization with purified protein, kinase assays on MBP, and kinase-dead mutagenesis in cells","pmids":["11124993"],"confidence":"High","gaps":["Physiological kinase substrates not identified","Regulation of the two activities in vivo unaddressed"]},{"year":2004,"claim":"Defined the C-terminus as an autoinhibitory module by showing its removal increases kinase activity ~10-fold, and that splice variants differ in subcellular localization.","evidence":"In vitro kinase assays on CaMK substrates with C-terminal truncation mutants and immunofluorescence","pmids":["14741399"],"confidence":"High","gaps":["Structural basis of autoinhibition not resolved","Physiological trigger for de-repression unknown"]},{"year":2016,"claim":"Identified neuronal roles for DCLK1: MAP7D1-Ser315 phosphorylation drives axon elongation and dendritic-microtubule labeling directs KIF1-dependent cargo, linking kinase and MAP functions to neuronal morphogenesis.","evidence":"Phosphoproteomic substrate ID with phosphomimetic rescue; kinesin family-wide screen and knockdown in neurons","pmids":["27503845","26758546"],"confidence":"High","gaps":["How DCLK1 selects dendritic microtubule subsets is unknown","Whether KIF1 guidance requires DCLK1 kinase activity not established"]},{"year":2021,"claim":"Resolved the autoinhibition mechanism structurally and identified its physiological release switch, showing the AID blocks the ATP site and HPCAL1 binds the AID in a Ca²⁺-dependent manner to activate the kinase.","evidence":"Crystal structure of the autoinhibited kinase domain plus HPCAL1–AID binding and Ca²⁺-activation assays; inhibitor co-crystals","pmids":["34977835","34545159"],"confidence":"High","gaps":["Whether HPCAL1 activation operates outside neurons unknown","Cellular contexts that supply the Ca²⁺ signal not mapped"]},{"year":2013,"claim":"Demonstrated an in vivo developmental role outside the nervous system, placing DCLK1 as a Runx2 antagonist controlling osteoblast differentiation and bone mass.","evidence":"Dclk1-null mice with bone phenotyping and Runx2+/-;Dclk1-/- double-mutant epistasis","pmids":["23918955"],"confidence":"High","gaps":["Molecular mechanism of Runx2 antagonism not defined","Whether kinase activity is required unaddressed"]},{"year":2016,"claim":"Established Dclk1+ cells as injury-responsive regenerative/cancer-initiating populations through lineage tracing and ablation, distinguishing tumor stem cells from normal stem cells.","evidence":"Dclk1-CreER lineage tracing and conditional cell ablation in pancreatitis/Kras and ApcMin/+ models","pmids":["27058937","23202126","24123696"],"confidence":"High","gaps":["Cell-intrinsic molecular program conferring stemness not fully defined","Relationship between marker status and DCLK1 enzymatic function unclear"]},{"year":2018,"claim":"Linked Dclk1 in tuft cells to injury-induced ATM activation and COX-2/PGE2 production driving epithelial proliferation, establishing a DNA-damage/inflammation axis.","evidence":"Conditional intestinal Dclk1 knockout, irradiation, Co-IP for Dclk1–ATM, and PGE2 organoid rescue","pmids":["27876863","30478383"],"confidence":"Medium","gaps":["Whether Dclk1–ATM interaction is direct/kinase-dependent not resolved","Paracrine signal identity incompletely defined"]},{"year":2013,"claim":"Positioned DCLK1 as a master repressor of tumor-suppressive miRNA networks (let-7a, miR-200, miR-145) controlling pluripotency factors, KRAS, and EMT transcription factors.","evidence":"siRNA knockdown with luciferase reporters and RT-PCR in colorectal/pancreatic cancer cells and xenografts","pmids":["19445940","21285251","24040120"],"confidence":"Medium","gaps":["Molecular mechanism by which DCLK1 controls miRNA biogenesis unknown","Whether kinase activity is required not established"]},{"year":2022,"claim":"Identified direct kinase substrates and binding partners driving cancer inflammation and stemness: IKKβ (NF-κB), XRCC5/Ku80 (COX-2/PGE2), and CCAR1 (β-catenin stabilization).","evidence":"Co-IP/LC-MS-MS partner identification, in vitro kinase assays on defined sites, and conditional KO/inhibition in vivo","pmids":["36896602","35910805","35522902"],"confidence":"Medium","gaps":["Substrate specificity determinants not mapped","Relative contribution of each substrate in vivo unclear"]},{"year":2022,"claim":"Defined DCLK1's role in immune evasion via CXCL1-mediated MDSC recruitment and M2 macrophage polarization suppressing CD8+ T-cell activity.","evidence":"CRISPR DCLK1 knockout with in vivo CXCL1 rescue, MDSC sorting/co-culture, and macrophage polarization assays","pmids":["36309200","32371580"],"confidence":"High","gaps":["Mechanism linking DCLK1 kinase activity to CXCL1 induction unresolved","Whether MDSC and M2 axes are independent not determined"]},{"year":2020,"claim":"Connected DCLK1 to additional cancer effectors: kinase-dependent extracellular-vesicle cargo selection, KRAS activation, and ERK/RhoA/YAP signaling driving EMT.","evidence":"Overexpression/knockout with sEV proteomics, RAS pull-down and Co-IP, ChIP, and pathway immunoblots across pancreatic/breast/lung models","pmids":["33991177","31467540","32755567","31223610","36369000","28179411","28148261"],"confidence":"Medium","gaps":["Direct versus indirect engagement of KRAS/RhoA/YAP not fully separated","CDK11 as a substrate remains preliminary"]},{"year":2019,"claim":"Explained how DCLK1 expression is itself reprogrammed in cancer: KDM3A H3K9 demethylation activates its promoter and an NF-κB/LEF1-driven alternate β-promoter produces a short oncogenic isoform.","evidence":"ChIP, promoter-reporter assays, gain/loss-of-function, and in vivo tumor models; miR-195/HuR 3'-UTR translational control","pmids":["31442435","26447334","30446587","33788631"],"confidence":"High","gaps":["Functional differences between long and short isoforms not fully resolved","Upstream signals selecting promoter usage incompletely defined"]},{"year":null,"claim":"It remains unresolved how DCLK1's MAP versus kinase functions and its long versus short isoforms are partitioned to dictate context-specific outcomes across neurons, epithelial regeneration, and the many cancer signaling axes attributed to it.","evidence":"No single study reconciles the activity/isoform partitioning across tissues","pmids":[],"confidence":"Low","gaps":["No unified model linking isoform expression to specific substrate engagement","Whether neuronal HPCAL1/Ca²⁺ activation operates in cancer cells untested","Which cancer phenotypes require catalytic activity versus MAP function not systematically dissected"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,6,8,17,29]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,8,17,29]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[0,1]},{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[3]}],"localization":[{"term_id":"GO:0005856","term_label":"cytoskeleton","supporting_discovery_ids":[0,1]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6]}],"pathway":[{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,11,23,25]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,16,28,29]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[8,23,31]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[1,2,7]},{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[19,20,21]}],"complexes":[],"partners":["HPCAL1","MAP7D1","IKBKB","XRCC5","CCAR1","ATM","KRAS","CDK11"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O15075","full_name":"Serine/threonine-protein kinase DCLK1","aliases":["Doublecortin domain-containing protein 3A","Doublecortin-like and CAM kinase-like 1","Doublecortin-like kinase 1"],"length_aa":740,"mass_kda":82.2,"function":"Probable kinase that may be involved in a calcium-signaling pathway controlling neuronal migration in the developing brain. May also participate in functions of the mature nervous system","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/O15075/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/DCLK1","classification":"Not Classified","n_dependent_lines":11,"n_total_lines":1208,"dependency_fraction":0.009105960264900662},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/DCLK1","total_profiled":1310},"omim":[{"mim_id":"621363","title":"MAP7 DOMAIN-CONTAINING PROTEIN 1; MAP7D1","url":"https://www.omim.org/entry/621363"},{"mim_id":"614994","title":"CALCIUM/CALMODULIN-DEPENDENT PROTEIN KINASE IG; CAMK1G","url":"https://www.omim.org/entry/614994"},{"mim_id":"613167","title":"DOUBLECORTIN-LIKE KINASE 3; DCLK3","url":"https://www.omim.org/entry/613167"},{"mim_id":"613166","title":"DOUBLECORTIN-LIKE KINASE 2; DCLK2","url":"https://www.omim.org/entry/613166"},{"mim_id":"607394","title":"POU DOMAIN, CLASS 2, TRANSCRIPTION FACTOR 3; POU2F3","url":"https://www.omim.org/entry/607394"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":93.3}],"url":"https://www.proteinatlas.org/search/DCLK1"},"hgnc":{"alias_symbol":["KIAA0369","DCLK","DCDC3A"],"prev_symbol":["DCAMKL1"]},"alphafold":{"accession":"O15075","domains":[{"cath_id":"3.10.20.230","chopping":"56-131","consensus_level":"high","plddt":85.7903,"start":56,"end":131},{"cath_id":"3.10.20.230","chopping":"185-280","consensus_level":"high","plddt":72.488,"start":185,"end":280},{"cath_id":"3.30.200.20","chopping":"384-465","consensus_level":"medium","plddt":91.4841,"start":384,"end":465},{"cath_id":"1.10.510.10","chopping":"470-685","consensus_level":"high","plddt":89.6544,"start":470,"end":685}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O15075","model_url":"https://alphafold.ebi.ac.uk/files/AF-O15075-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O15075-F1-predicted_aligned_error_v6.png","plddt_mean":72.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=DCLK1","jax_strain_url":"https://www.jax.org/strain/search?query=DCLK1"},"sequence":{"accession":"O15075","fasta_url":"https://rest.uniprot.org/uniprotkb/O15075.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O15075/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O15075"}},"corpus_meta":[{"pmid":"23202126","id":"PMC_23202126","title":"Dclk1 distinguishes between tumor and normal stem cells in the intestine.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23202126","citation_count":336,"is_preprint":false},{"pmid":"24096005","id":"PMC_24096005","title":"DCLK1 marks a morphologically distinct subpopulation of cells with stem cell properties in preinvasive pancreatic cancer.","date":"2013","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/24096005","citation_count":265,"is_preprint":false},{"pmid":"27058937","id":"PMC_27058937","title":"Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis.","date":"2016","source":"Cell stem cell","url":"https://pubmed.ncbi.nlm.nih.gov/27058937","citation_count":191,"is_preprint":false},{"pmid":"21285251","id":"PMC_21285251","title":"DCAMKL-1 regulates epithelial-mesenchymal transition in human pancreatic cells through a miR-200a-dependent mechanism.","date":"2011","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/21285251","citation_count":182,"is_preprint":false},{"pmid":"11124993","id":"PMC_11124993","title":"DCAMKL1 encodes a protein kinase with homology to doublecortin that regulates microtubule polymerization.","date":"2000","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/11124993","citation_count":166,"is_preprint":false},{"pmid":"26758546","id":"PMC_26758546","title":"Microtubule-binding protein doublecortin-like kinase 1 (DCLK1) guides kinesin-3-mediated cargo transport to dendrites.","date":"2016","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/26758546","citation_count":139,"is_preprint":false},{"pmid":"24040120","id":"PMC_24040120","title":"DCLK1 regulates pluripotency and angiogenic factors via microRNA-dependent mechanisms in pancreatic cancer.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24040120","citation_count":123,"is_preprint":false},{"pmid":"24880079","id":"PMC_24880079","title":"XMD8-92 inhibits pancreatic tumor xenograft growth via a DCLK1-dependent mechanism.","date":"2014","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/24880079","citation_count":111,"is_preprint":false},{"pmid":"24626093","id":"PMC_24626093","title":"Curcumin promotes autophagic survival of a subset of colon cancer stem cells, which are ablated by DCLK1-siRNA.","date":"2014","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/24626093","citation_count":104,"is_preprint":false},{"pmid":"21688022","id":"PMC_21688022","title":"Gastric tuft cells express DCLK1 and are expanded in hyperplasia.","date":"2011","source":"Histochemistry and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21688022","citation_count":102,"is_preprint":false},{"pmid":"19445940","id":"PMC_19445940","title":"Selective blockade of DCAMKL-1 results in tumor growth arrest by a Let-7a MicroRNA-dependent mechanism.","date":"2009","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/19445940","citation_count":101,"is_preprint":false},{"pmid":"28148261","id":"PMC_28148261","title":"Dclk1, a tumor stem cell marker, regulates pro-survival signaling and self-renewal of intestinal tumor cells.","date":"2017","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/28148261","citation_count":93,"is_preprint":false},{"pmid":"25605241","id":"PMC_25605241","title":"DCLK1 is a broadly dysregulated target against epithelial-mesenchymal transition, focal adhesion, and stemness in clear cell renal carcinoma.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25605241","citation_count":85,"is_preprint":false},{"pmid":"30478383","id":"PMC_30478383","title":"Dclk1 in tuft cells promotes inflammation-driven epithelial restitution and mitigates chronic colitis.","date":"2018","source":"Cell death and differentiation","url":"https://pubmed.ncbi.nlm.nih.gov/30478383","citation_count":83,"is_preprint":false},{"pmid":"28684459","id":"PMC_28684459","title":"Dclk1-expressing tuft cells: critical modulators of the intestinal niche?","date":"2017","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/28684459","citation_count":81,"is_preprint":false},{"pmid":"29277893","id":"PMC_29277893","title":"DCLK1 promotes epithelial-mesenchymal transition via the PI3K/Akt/NF-κB pathway in colorectal cancer.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29277893","citation_count":75,"is_preprint":false},{"pmid":"25211188","id":"PMC_25211188","title":"DCLK1 facilitates intestinal tumor growth via enhancing pluripotency and epithelial mesenchymal transition.","date":"2014","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25211188","citation_count":73,"is_preprint":false},{"pmid":"9747029","id":"PMC_9747029","title":"Expression and chromosomal localization of KIAA0369, a putative kinase structurally related to Doublecortin.","date":"1998","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/9747029","citation_count":71,"is_preprint":false},{"pmid":"24123696","id":"PMC_24123696","title":"Brief report: Dclk1 deletion in tuft cells results in impaired epithelial repair after radiation injury.","date":"2014","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/24123696","citation_count":71,"is_preprint":false},{"pmid":"26747706","id":"PMC_26747706","title":"miR-137 Regulates the Tumorigenicity of Colon Cancer Stem Cells through the Inhibition of DCLK1.","date":"2016","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/26747706","citation_count":71,"is_preprint":false},{"pmid":"10533048","id":"PMC_10533048","title":"KIAA0369, doublecortin-like kinase, is expressed during brain development.","date":"1999","source":"Journal of neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/10533048","citation_count":69,"is_preprint":false},{"pmid":"26764906","id":"PMC_26764906","title":"Dominant Expression of DCLK1 in Human Pancreatic Cancer Stem Cells Accelerates Tumor Invasion and Metastasis.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/26764906","citation_count":68,"is_preprint":false},{"pmid":"20522640","id":"PMC_20522640","title":"Identification of a novel putative pancreatic stem/progenitor cell marker DCAMKL-1 in normal mouse pancreas.","date":"2010","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/20522640","citation_count":66,"is_preprint":false},{"pmid":"31979136","id":"PMC_31979136","title":"Cancer Stem Cell Marker DCLK1 Correlates with Tumorigenic Immune Infiltrates in the Colon and Gastric Adenocarcinoma Microenvironments.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31979136","citation_count":65,"is_preprint":false},{"pmid":"31442435","id":"PMC_31442435","title":"The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.","date":"2019","source":"Gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/31442435","citation_count":64,"is_preprint":false},{"pmid":"29577277","id":"PMC_29577277","title":"Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/29577277","citation_count":63,"is_preprint":false},{"pmid":"26447334","id":"PMC_26447334","title":"Epigenetic changes and alternate promoter usage by human colon cancers for expressing DCLK1-isoforms: Clinical Implications.","date":"2015","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/26447334","citation_count":61,"is_preprint":false},{"pmid":"27458755","id":"PMC_27458755","title":"Functional implication of Dclk1 and Dclk1-expressing cells in cancer.","date":"2016","source":"Small GTPases","url":"https://pubmed.ncbi.nlm.nih.gov/27458755","citation_count":60,"is_preprint":false},{"pmid":"30446587","id":"PMC_30446587","title":"Inhibition of LEF1-Mediated DCLK1 by Niclosamide Attenuates Colorectal Cancer Stemness.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30446587","citation_count":59,"is_preprint":false},{"pmid":"10550327","id":"PMC_10550327","title":"High expression of doublecortin and KIAA0369 protein in fetal brain suggests their specific role in neuronal migration.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10550327","citation_count":57,"is_preprint":false},{"pmid":"10036192","id":"PMC_10036192","title":"DCAMKL1, a brain-specific transmembrane protein on 13q12.3 that is similar to doublecortin (DCX).","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10036192","citation_count":57,"is_preprint":false},{"pmid":"29224010","id":"PMC_29224010","title":"MicroRNA-195 Suppresses the Progression of Pancreatic Cancer by Targeting DCLK1.","date":"2017","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/29224010","citation_count":55,"is_preprint":false},{"pmid":"23918955","id":"PMC_23918955","title":"The microtubule-associated protein DCAMKL1 regulates osteoblast function via repression of Runx2.","date":"2013","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23918955","citation_count":54,"is_preprint":false},{"pmid":"35157971","id":"PMC_35157971","title":"Inhibition of DCLK1 sensitizes resistant lung adenocarcinomas to EGFR-TKI through suppression of Wnt/β-Catenin activity and cancer stemness.","date":"2022","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/35157971","citation_count":52,"is_preprint":false},{"pmid":"22557932","id":"PMC_22557932","title":"DCLK1 immunoreactivity in colorectal neoplasia.","date":"2012","source":"Clinical and experimental gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/22557932","citation_count":51,"is_preprint":false},{"pmid":"24384857","id":"PMC_24384857","title":"The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer.","date":"2014","source":"Epigenetics","url":"https://pubmed.ncbi.nlm.nih.gov/24384857","citation_count":51,"is_preprint":false},{"pmid":"30449704","id":"PMC_30449704","title":"Enhancement of Sensitivity to Chemo/Radiation Therapy by Using miR-15b against DCLK1 in Colorectal Cancer.","date":"2018","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30449704","citation_count":50,"is_preprint":false},{"pmid":"27335684","id":"PMC_27335684","title":"Regulatory Roles of Dclk1 in Epithelial Mesenchymal Transition and Cancer Stem Cells.","date":"2016","source":"Journal of carcinogenesis & mutagenesis","url":"https://pubmed.ncbi.nlm.nih.gov/27335684","citation_count":49,"is_preprint":false},{"pmid":"26468984","id":"PMC_26468984","title":"Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26468984","citation_count":46,"is_preprint":false},{"pmid":"33350586","id":"PMC_33350586","title":"Extracellular vesicles-encapsulated let-7i shed from bone mesenchymal stem cells suppress lung cancer via KDM3A/DCLK1/FXYD3 axis.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33350586","citation_count":46,"is_preprint":false},{"pmid":"31878090","id":"PMC_31878090","title":"DCLK1 Monoclonal Antibody-Based CAR-T Cells as a Novel Treatment Strategy against Human Colorectal Cancers.","date":"2019","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/31878090","citation_count":46,"is_preprint":false},{"pmid":"36896602","id":"PMC_36896602","title":"Macrophage DCLK1 promotes atherosclerosis via binding to IKKβ and inducing inflammatory responses.","date":"2023","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36896602","citation_count":45,"is_preprint":false},{"pmid":"26362399","id":"PMC_26362399","title":"Dclk1+ small intestinal epithelial tuft cells display the hallmarks of quiescence and self-renewal.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26362399","citation_count":45,"is_preprint":false},{"pmid":"27049311","id":"PMC_27049311","title":"miR-613 inhibits the growth and invasiveness of human hepatocellular carcinoma via targeting DCLK1.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/27049311","citation_count":45,"is_preprint":false},{"pmid":"29416778","id":"PMC_29416778","title":"Modified miR-15a has therapeutic potential for improving treatment of advanced stage colorectal cancer through inhibition of BCL2, BMI1, YAP1 and DCLK1.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29416778","citation_count":44,"is_preprint":false},{"pmid":"32423385","id":"PMC_32423385","title":"LncRNA SNHG1 promotes EMT process in gastric cancer cells through regulation of the miR-15b/DCLK1/Notch1 axis.","date":"2020","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/32423385","citation_count":41,"is_preprint":false},{"pmid":"30119173","id":"PMC_30119173","title":"RETRACTED: miR-539 enhances chemosensitivity to cisplatin in non-small cell lung cancer by targeting DCLK1.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30119173","citation_count":41,"is_preprint":false},{"pmid":"33348546","id":"PMC_33348546","title":"Tuft and Cancer Stem Cell Marker DCLK1: A New Target to Enhance Anti-Tumor Immunity in the Tumor Microenvironment.","date":"2020","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/33348546","citation_count":40,"is_preprint":false},{"pmid":"33753110","id":"PMC_33753110","title":"LncRNA SNHG1 contributes to the cisplatin resistance and progression of NSCLC via miR-330-5p/DCLK1 axis.","date":"2021","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/33753110","citation_count":40,"is_preprint":false},{"pmid":"15614772","id":"PMC_15614772","title":"Expression of doublecortin (DCX) and doublecortin-like kinase (DCLK) within the developing chick brain.","date":"2005","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/15614772","citation_count":38,"is_preprint":false},{"pmid":"32978808","id":"PMC_32978808","title":"DCLK1, a Putative Stem Cell Marker in Human Cholangiocarcinoma.","date":"2021","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/32978808","citation_count":38,"is_preprint":false},{"pmid":"32637578","id":"PMC_32637578","title":"DCLK1 Regulates Tumor Stemness and Cisplatin Resistance in Non-small Cell Lung Cancer via ABCD-Member-4.","date":"2020","source":"Molecular therapy oncolytics","url":"https://pubmed.ncbi.nlm.nih.gov/32637578","citation_count":38,"is_preprint":false},{"pmid":"31223610","id":"PMC_31223610","title":"DCLK1 Plays a Metastatic-Promoting Role in Human Breast Cancer Cells.","date":"2019","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/31223610","citation_count":37,"is_preprint":false},{"pmid":"27503845","id":"PMC_27503845","title":"DCLK1 phosphorylates the microtubule-associated protein MAP7D1 to promote axon elongation in cortical neurons.","date":"2016","source":"Developmental neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/27503845","citation_count":37,"is_preprint":false},{"pmid":"25631749","id":"PMC_25631749","title":"Upregulation of circulating cancer stem cell marker, DCLK1 but not Lgr5, in chemoradiotherapy-treated colorectal cancer patients.","date":"2015","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25631749","citation_count":37,"is_preprint":false},{"pmid":"34977835","id":"PMC_34977835","title":"DCLK1 autoinhibition and activation in tumorigenesis.","date":"2021","source":"Innovation (Cambridge (Mass.))","url":"https://pubmed.ncbi.nlm.nih.gov/34977835","citation_count":36,"is_preprint":false},{"pmid":"32371580","id":"PMC_32371580","title":"DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32371580","citation_count":36,"is_preprint":false},{"pmid":"14741399","id":"PMC_14741399","title":"Functional differences between two DCLK splice variants.","date":"2004","source":"Brain research. Molecular brain research","url":"https://pubmed.ncbi.nlm.nih.gov/14741399","citation_count":36,"is_preprint":false},{"pmid":"28179411","id":"PMC_28179411","title":"Pancreatic Neuroendocrine Tumors and EMT Behavior Are Driven by the CSC Marker DCLK1.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28179411","citation_count":36,"is_preprint":false},{"pmid":"31467540","id":"PMC_31467540","title":"Overexpression of DCLK1-AL Increases Tumor Cell Invasion, Drug Resistance, and KRAS Activation and Can Be Targeted to Inhibit Tumorigenesis in Pancreatic Cancer.","date":"2019","source":"Journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/31467540","citation_count":36,"is_preprint":false},{"pmid":"10051403","id":"PMC_10051403","title":"Genomic structure, chromosomal mapping, and expression pattern of human DCAMKL1 (KIAA0369), a homologue of DCX (XLIS).","date":"1999","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/10051403","citation_count":35,"is_preprint":false},{"pmid":"27876863","id":"PMC_27876863","title":"Intestinal tuft cells regulate the ATM mediated DNA Damage response via Dclk1 dependent mechanism for crypt restitution following radiation injury.","date":"2016","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/27876863","citation_count":35,"is_preprint":false},{"pmid":"24368703","id":"PMC_24368703","title":"Inhibition of Notch signaling reduces the number of surviving Dclk1+ reserve crypt epithelial stem cells following radiation injury.","date":"2013","source":"American journal of physiology. Gastrointestinal and liver physiology","url":"https://pubmed.ncbi.nlm.nih.gov/24368703","citation_count":34,"is_preprint":false},{"pmid":"35910805","id":"PMC_35910805","title":"DCLK1 promotes colorectal cancer stemness and aggressiveness via the XRCC5/COX2 axis.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35910805","citation_count":32,"is_preprint":false},{"pmid":"31837335","id":"PMC_31837335","title":"Inhibition of DCLK1 down-regulates PD-L1 expression through Hippo pathway in human pancreatic cancer.","date":"2019","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31837335","citation_count":32,"is_preprint":false},{"pmid":"25283374","id":"PMC_25283374","title":"DCLK1 is detectable in plasma of patients with Barrett's esophagus and esophageal adenocarcinoma.","date":"2014","source":"Digestive diseases and sciences","url":"https://pubmed.ncbi.nlm.nih.gov/25283374","citation_count":31,"is_preprint":false},{"pmid":"28414327","id":"PMC_28414327","title":"A novel antibody against cancer stem cell biomarker, DCLK1-S, is potentially useful for assessing colon cancer risk after screening colonoscopy.","date":"2017","source":"Laboratory investigation; a journal of technical methods and pathology","url":"https://pubmed.ncbi.nlm.nih.gov/28414327","citation_count":31,"is_preprint":false},{"pmid":"35522902","id":"PMC_35522902","title":"Targeting DCLK1 overcomes 5-fluorouracil resistance in colorectal cancer through inhibiting CCAR1/β-catenin pathway-mediated cancer stemness.","date":"2022","source":"Clinical and translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35522902","citation_count":29,"is_preprint":false},{"pmid":"27287716","id":"PMC_27287716","title":"Survival of Patients with Gastrointestinal Cancers Can Be Predicted by a Surrogate microRNA Signature for Cancer Stem-like Cells Marked by DCLK1 Kinase.","date":"2016","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/27287716","citation_count":28,"is_preprint":false},{"pmid":"36250024","id":"PMC_36250024","title":"Pleiotropic effects of DCLK1 in cancer and cancer stem cells.","date":"2022","source":"Frontiers in molecular biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/36250024","citation_count":27,"is_preprint":false},{"pmid":"33788631","id":"PMC_33788631","title":"MicroRNA-195 regulates Tuft cell function in the intestinal epithelium by altering translation of DCLK1.","date":"2021","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/33788631","citation_count":26,"is_preprint":false},{"pmid":"34830884","id":"PMC_34830884","title":"Inhibition of DCLK1 with DCLK1-IN-1 Suppresses Renal Cell Carcinoma Invasion and Stemness and Promotes Cytotoxic T-Cell-Mediated Anti-Tumor Immunity.","date":"2021","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/34830884","citation_count":26,"is_preprint":false},{"pmid":"25948779","id":"PMC_25948779","title":"Inflammatory and oncogenic roles of a tumor stem cell marker doublecortin-like kinase (DCLK1) in virus-induced chronic liver diseases.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25948779","citation_count":26,"is_preprint":false},{"pmid":"27777940","id":"PMC_27777940","title":"Epigenetic regulation of human DCLK-1 gene during colon-carcinogenesis: clinical and mechanistic implications.","date":"2016","source":"Stem cell investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27777940","citation_count":25,"is_preprint":false},{"pmid":"34545159","id":"PMC_34545159","title":"Structural basis for small molecule targeting of Doublecortin Like Kinase 1 with DCLK1-IN-1.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34545159","citation_count":25,"is_preprint":false},{"pmid":"33991177","id":"PMC_33991177","title":"Cancer stem cell marker DCLK1 reprograms small extracellular vesicles toward migratory phenotype in gastric cancer cells.","date":"2021","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/33991177","citation_count":25,"is_preprint":false},{"pmid":"37443105","id":"PMC_37443105","title":"Macrophage DCLK1 promotes obesity-induced cardiomyopathy via activating RIP2/TAK1 signaling pathway.","date":"2023","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/37443105","citation_count":24,"is_preprint":false},{"pmid":"34998236","id":"PMC_34998236","title":"Inhibition of DCLK1 kinase reverses epithelial-mesenchymal transition and restores T-cell activity in pancreatic ductal adenocarcinoma.","date":"2022","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34998236","citation_count":24,"is_preprint":false},{"pmid":"22539971","id":"PMC_22539971","title":"DCLK1 variants are associated across schizophrenia and attention deficit/hyperactivity disorder.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22539971","citation_count":24,"is_preprint":false},{"pmid":"22749579","id":"PMC_22749579","title":"Immunolocalization of DCAMKL-1, a putative intestinal stem cell marker, in normal colonic tissue.","date":"2012","source":"Pathology, research and practice","url":"https://pubmed.ncbi.nlm.nih.gov/22749579","citation_count":23,"is_preprint":false},{"pmid":"37069669","id":"PMC_37069669","title":"Targeting DCLK1 attenuates tumor stemness and evokes antitumor immunity in triple-negative breast cancer by inhibiting IL-6/STAT3 signaling.","date":"2023","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/37069669","citation_count":22,"is_preprint":false},{"pmid":"20565818","id":"PMC_20565818","title":"Altered expression of a putative progenitor cell marker DCAMKL1 in the rat gastric mucosa in regeneration, metaplasia and dysplasia.","date":"2010","source":"BMC gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/20565818","citation_count":22,"is_preprint":false},{"pmid":"29656186","id":"PMC_29656186","title":"DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/29656186","citation_count":22,"is_preprint":false},{"pmid":"34336664","id":"PMC_34336664","title":"Doublecortin-Like Kinase 1 (DCLK1) Is a Novel NOTCH Pathway Signaling Regulator in Head and Neck Squamous Cell Carcinoma.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34336664","citation_count":22,"is_preprint":false},{"pmid":"27802206","id":"PMC_27802206","title":"Evaluation of circulating cellular DCLK1 protein, as the most promising colorectal cancer stem cell marker, using immunoassay based methods.","date":"2016","source":"Cancer biomarkers : section A of Disease markers","url":"https://pubmed.ncbi.nlm.nih.gov/27802206","citation_count":22,"is_preprint":false},{"pmid":"30396941","id":"PMC_30396941","title":"Dclk1 Inhibition Cancels 5-FU-induced Cell-cycle Arrest and Decreases Cell Survival in Colorectal Cancer.","date":"2018","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/30396941","citation_count":21,"is_preprint":false},{"pmid":"31773701","id":"PMC_31773701","title":"DCLK1 promotes malignant progression of breast cancer by regulating Wnt/β-Catenin signaling pathway.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31773701","citation_count":21,"is_preprint":false},{"pmid":"34610960","id":"PMC_34610960","title":"DCLK1-Short Splice Variant Promotes Esophageal Squamous Cell Carcinoma Progression via the MAPK/ERK/MMP2 Pathway.","date":"2021","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/34610960","citation_count":20,"is_preprint":false},{"pmid":"31028726","id":"PMC_31028726","title":"Increased expression of DCLK1, a novel putative CSC maker, is associated with tumor aggressiveness and worse disease-specific survival in patients with bladder carcinomas.","date":"2019","source":"Experimental and molecular pathology","url":"https://pubmed.ncbi.nlm.nih.gov/31028726","citation_count":20,"is_preprint":false},{"pmid":"34733368","id":"PMC_34733368","title":"DCLK1 and its interaction partners: An effective therapeutic target for colorectal cancer.","date":"2021","source":"Oncology letters","url":"https://pubmed.ncbi.nlm.nih.gov/34733368","citation_count":19,"is_preprint":false},{"pmid":"32530623","id":"PMC_32530623","title":"Synthesis and Structure-Activity Relationships of DCLK1 Kinase Inhibitors Based on a 5,11-Dihydro-6H-benzo[e]pyrimido[5,4-b][1,4]diazepin-6-one Scaffold.","date":"2020","source":"Journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32530623","citation_count":19,"is_preprint":false},{"pmid":"27900578","id":"PMC_27900578","title":"Potential Mechanism of Neurite Outgrowth Enhanced by Electrical Stimulation: Involvement of MicroRNA-363-5p Targeting DCLK1 Expression in Rat.","date":"2016","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/27900578","citation_count":19,"is_preprint":false},{"pmid":"18075264","id":"PMC_18075264","title":"Alternative transcripts of Dclk1 and Dclk2 and their expression in doublecortin knockout mice.","date":"2008","source":"Developmental neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/18075264","citation_count":18,"is_preprint":false},{"pmid":"34226497","id":"PMC_34226497","title":"DCLK1 isoforms and aberrant Notch signaling in the regulation of human and murine colitis.","date":"2021","source":"Cell death discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34226497","citation_count":18,"is_preprint":false},{"pmid":"35404759","id":"PMC_35404759","title":"Long noncoding RNA BMPR1B-AS1 facilitates endometrial cancer cell proliferation and metastasis by sponging miR-7-2-3p to modulate the DCLK1/Akt/NF-κB pathway.","date":"2022","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/35404759","citation_count":18,"is_preprint":false},{"pmid":"36309200","id":"PMC_36309200","title":"DCLK1 Suppresses Tumor-Specific Cytotoxic T Lymphocyte Function Through Recruitment of MDSCs via the CXCL1-CXCR2 Axis.","date":"2022","source":"Cellular and molecular gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/36309200","citation_count":18,"is_preprint":false},{"pmid":"29526803","id":"PMC_29526803","title":"Pancreatic DCLK1+ cells originate distinctly from PDX1+ progenitors and contribute to the initiation of intraductal papillary mucinous neoplasm in mice.","date":"2018","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/29526803","citation_count":18,"is_preprint":false},{"pmid":"36369000","id":"PMC_36369000","title":"Thrombin induces IL-8/CXCL8 expression by DCLK1-dependent RhoA and YAP activation in human lung epithelial cells.","date":"2022","source":"Journal of biomedical science","url":"https://pubmed.ncbi.nlm.nih.gov/36369000","citation_count":17,"is_preprint":false},{"pmid":"32755567","id":"PMC_32755567","title":"Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.","date":"2020","source":"Cell chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/32755567","citation_count":17,"is_preprint":false},{"pmid":"36148883","id":"PMC_36148883","title":"Role of DCLK1 in oncogenic signaling (Review).","date":"2022","source":"International journal of oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36148883","citation_count":16,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":54746,"output_tokens":9713,"usd":0.154967,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19907,"output_tokens":4658,"usd":0.107993,"stage2_stop_reason":"end_turn"},"total_usd":0.26296,"stage1_batch_id":"msgbatch_01AsR7g8dGTEiEw9U83bJeWn","stage2_batch_id":"msgbatch_01YV5ZyxtFNUZEjxRcpd9jzb","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"DCAMKL1/DCLK1 protein associates with microtubules and stimulates polymerization of purified tubulin, forming aster-like microtubule structures. Overexpressed DCAMKL1 causes striking microtubule bundling in cell lines and primary neural cells. DCAMKL1 also encodes a functional kinase capable of phosphorylating myelin basic protein and itself (autophosphorylation). Elimination of kinase activity has no detectable effect on microtubule polymerization activity, indicating these two functions are separable.\",\n      \"method\": \"In vitro microtubule polymerization assay with purified protein; overexpression in cell lines; kinase activity assay with MBP substrate; kinase-dead mutagenesis; time-lapse live-cell imaging of GFP-fusion\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with purified protein, mutagenesis separating kinase from MAP function, multiple orthogonal methods in one rigorous study\",\n      \"pmids\": [\"11124993\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DCLK1 labels a subset of dendritic microtubules and is required for kinesin-3 (KIF1)-dependent dense-core vesicle trafficking into dendrites and for dendrite development. Screening of all 45 kinesin family members identified KIF1/kinesin-3 and KIF21/kinesin-4 subfamily members as capable of dendritic transport; DCLK1 on dendritic microtubules provides local signals directing KIF1-dependent cargo specifically to dendrites.\",\n      \"method\": \"Kinesin family-wide screen in living cells; live imaging of cargo transport in hippocampal neurons; DCLK1 knockdown with phenotypic readout (DCV trafficking, dendrite development)\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — systematic screen plus KD with specific cellular phenotype, multiple orthogonal methods, single rigorous study\",\n      \"pmids\": [\"26758546\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DCLK1 phosphorylates MAP7D1 (microtubule-associated protein 7 domain containing 1) at serine 315 to promote axon elongation of cortical neurons. MAP7D1 was identified as a DCLK1 substrate by proteomic analysis; knockdown of MAP7D1 impairs callosal axon elongation but not radial migration. Overexpression of phosphomimetic MAP7D1-S315E fully rescues axon elongation defects in Dclk1-knockdown neurons, whereas wild-type MAP7D1 does not.\",\n      \"method\": \"Phosphoproteomics/proteomic substrate identification; shRNA knockdown in cortical neurons; in utero electroporation; phosphomimetic rescue experiment\",\n      \"journal\": \"Developmental neurobiology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — substrate identified by proteomics, phosphorylation site defined, phosphomimetic rescue validates functional relevance, multiple orthogonal methods\",\n      \"pmids\": [\"27503845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"DCLK1 kinase domain adopts an autoinhibited state in which the C-terminal autoinhibitory domain (AID) blocks the ATP-binding site competitively with ATP. The neuronal calcium sensor HPCAL1 binds directly to the AID in a Ca²⁺-dependent manner, releasing autoinhibition and activating DCLK1 kinase activity. Cancer-associated mutations in the AID disrupt autoinhibition to upregulate kinase activity.\",\n      \"method\": \"Crystal structure of DCLK1 kinase domain in autoinhibited state; biochemical binding assays (HPCAL1–AID interaction); Ca²⁺-dependent activation assay; analysis of cancer-associated AID mutations\",\n      \"journal\": \"Innovation (Cambridge (Mass.))\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus biochemical validation of activator binding and mutational analysis, multiple orthogonal methods in one study\",\n      \"pmids\": [\"34977835\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Crystal structures of the DCLK1 kinase domain in complex with selective inhibitor DCLK1-IN-1 and its precursors were determined, revealing that DCLK1-IN-1 induces a drastic conformational change of the ATP binding site explaining its high selectivity. DCLK1-IN-1 binds DCLK1 long isoforms but does not prevent DCLK1's microtubule-associated protein (MAP) function.\",\n      \"method\": \"X-ray crystallography of kinase domain–inhibitor co-crystals; structure-activity relationship analysis; functional assay distinguishing kinase vs. MAP activity\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structures with SAR validation and functional dissection of MAP vs. kinase activity\",\n      \"pmids\": [\"34545159\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Using a DCLK1 chemical biology toolkit (inhibitor DCLK1-IN-1, inhibitor-resistant G532A mutant, kinase-dead D511N and D533N mutants), DCLK1 kinase activity was linked to RNA processing. Phosphoproteomics identified CDK11 as a potential substrate of DCLK1 kinase activity.\",\n      \"method\": \"Pharmacological inhibition with DCLK1-IN-1; engineered inhibitor-resistant and kinase-dead cell lines; phosphoproteomics\",\n      \"journal\": \"Cell chemical biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — phosphoproteomics with genetic controls (resistant mutant, kinase-dead), single lab, substrate identification is preliminary\",\n      \"pmids\": [\"32755567\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Two DCLK-short splice variants (DCLK-short-A and -B) both phosphorylate autocamtide and syntide (CaMK-specific substrates), confirming kinase activity. Removal of the C-terminal end of DCLK-short produces a ~10-fold increase in kinase activity, demonstrating that distinct C-termini function as autoinhibitory domains. The two variants localize differently: both are cytoplasmic, but DCLK-short-B also localizes to growth-cone-like structures and near the nucleus.\",\n      \"method\": \"In vitro kinase assay with CaMK substrates; C-terminal truncation mutagenesis; immunofluorescence localization in cells\",\n      \"journal\": \"Brain research. Molecular brain research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro kinase assay with mutagenesis demonstrating autoinhibitory domain, combined with localization data\",\n      \"pmids\": [\"14741399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DCAMKL1 represses osteoblast differentiation/activation by antagonizing Runx2, the master transcription factor of osteoblasts. Dcamkl1-null mice display elevated bone mass secondary to increased bone formation by osteoblasts. Genetic epistasis showed that key elements of the cleidocranial dysplasia phenotype in Runx2+/- mice are reversed by introduction of a Dcamkl1-null allele, establishing in vivo genetic linkage between DCAMKL1 and Runx2.\",\n      \"method\": \"Targeted gene disruption (Dcamkl1-null mice); shRNA screen (forward genetic); bone mass phenotyping; Runx2+/-;Dcamkl1-/- double-mutant epistasis\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis with double-mutant in vivo rescue, multiple orthogonal methods, defines mechanistic pathway position\",\n      \"pmids\": [\"23918955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Macrophage DCLK1 promotes atherosclerosis by directly interacting with IKKβ and phosphorylating IKKβ at S177/181, thereby facilitating NF-κB activation and inflammatory gene expression. Coimmunoprecipitation followed by LC-MS/MS identified IKKβ as a DCLK1-binding protein; macrophage-specific DCLK1 deletion attenuates atherosclerosis in ApoE-/- mice.\",\n      \"method\": \"Co-immunoprecipitation + LC-MS/MS; in vitro kinase assay on IKKβ; macrophage-specific conditional knockout mice; pharmacological DCLK1 inhibition in vivo\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — substrate/binding partner identified by Co-IP+MS, kinase activity on IKKβ demonstrated, validated with macrophage-specific KO and pharmacological inhibition\",\n      \"pmids\": [\"36896602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Macrophage-specific DCLK1 knockout (but not cardiomyocyte-specific knockout) prevents high-fat diet-induced cardiac dysfunction, hypertrophy, and fibrosis. DCLK1 mediates RIP2/TAK1 phosphorylation and subsequent inflammatory cytokine release in macrophages exposed to palmitate/HFD, which promotes hypertrophy in cardiomyocytes and fibrosis in fibroblasts.\",\n      \"method\": \"Cell-type-specific conditional knockout mice; RNA sequencing; in vitro macrophage-cardiomyocyte/fibroblast co-culture; pharmacological DCLK1 inhibition in vivo\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-type-specific KO with defined phenotype and RNA-seq, single lab\",\n      \"pmids\": [\"37443105\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"DCAMKL-1 is a negative regulator of let-7a miRNA biogenesis in intestinal stem and colorectal cancer cells. siRNA-mediated knockdown of DCAMKL-1 in colon cancer cells and xenografts results in increased pri-let-7a miRNA, decreased luciferase activity from a let-7a reporter, and decreased c-Myc expression. DCAMKL-1+ cells isolated by FACS have significantly lower pri-let-7a compared with more differentiated cells.\",\n      \"method\": \"siRNA knockdown; luciferase reporter assay for let-7a; FACS isolation of DCAMKL-1+ cells; tumor xenograft growth assay; real-time RT-PCR\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA KD with multiple readouts (luciferase reporter + endogenous target + xenograft), single lab\",\n      \"pmids\": [\"19445940\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"DCAMKL-1 knockdown in human pancreatic cancer cells induces miR-200a (an EMT inhibitor), with downregulation of EMT transcription factors ZEB1, ZEB2, Snail, Slug, and Twist. Additionally, DCAMKL-1 knockdown downregulates c-Myc and KRAS through a let-7a-dependent mechanism and downregulates Notch-1 through a miR-144-dependent mechanism, establishing DCAMKL-1 as a regulator of multiple miRNA-dependent pathways controlling EMT.\",\n      \"method\": \"siRNA knockdown in pancreatic cancer cells; miRNA quantification by RT-PCR; immunoblot for downstream targets; KRAS transgenic mouse model colocalization\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA with multiple downstream pathway readouts, single lab\",\n      \"pmids\": [\"21285251\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"DCLK1 knockdown using nanoparticle-encapsulated siRNA in pancreatic xenografts results in increased miR-145, leading to decreased pluripotency factors OCT4, SOX2, NANOG, KLF4, KRAS, and RREB1; increased let-7a, decreasing LIN28B; and increased miR-200, decreasing VEGFR1, VEGFR2, and EMT transcription factors. Luciferase-based reporter assays confirmed DCLK1-dependent post-transcriptional regulation of miR-145, miR-200, and let-7a downstream targets.\",\n      \"method\": \"siRNA nanoparticle delivery in xenograft model; luciferase reporter assay; immunoblot; RT-PCR\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays confirm direct regulation, in vivo xenograft validation, single lab\",\n      \"pmids\": [\"24040120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"DCLK1 induces NF-κBp65 subunit expression through the PI3K/Akt/Sp1 axis and activates NF-κBp65 through the PI3K/Akt/IκBα pathway during EMT in colorectal cancer cells. Silencing DCLK1 inhibits invasion and metastasis in vivo.\",\n      \"method\": \"siRNA knockdown; pharmacological pathway inhibitors; immunoblot for pathway components; in vivo xenograft invasion assay\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KD with pharmacological pathway dissection and in vivo validation, single lab\",\n      \"pmids\": [\"29277893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Dclk1 expression in tuft cells is important for inflammation-induced COX2 expression and prostaglandin E2 (PGE2) production in vivo. Loss of Dclk1 in intestinal epithelial cells impairs inflammation-induced proliferative response of colonic organoids, and exogenous PGE2 rescues proliferative defects in Dclk1-deficient organoids. Dclk1 is required for Dclk1-ATM interaction and COX2 activation in response to injury.\",\n      \"method\": \"Conditional intestinal epithelial Dclk1 knockout mice; organoid culture; PGE2 rescue experiment; immunostaining; qPCR\",\n      \"journal\": \"Cell death and differentiation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with organoid rescue experiment, specific molecular mechanism (COX2/PGE2), single lab\",\n      \"pmids\": [\"30478383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Dclk1 expressed in tuft cells regulates ATM-mediated DNA damage response following radiation injury. Isolated intestinal epithelial cells from VillinCre;Dclk1f/f mice showed reduced injury-induced ATM and COX2 activation, reduced pro-survival gene expression, and reduced self-renewal ability. Interaction with Dclk1 is critical for ATM activation. Dclk1+ tuft cells regulate the broader intestinal epithelium through a paracrine mechanism.\",\n      \"method\": \"Conditional intestinal epithelial Dclk1 knockout mice; total body irradiation; ATM pathway assessment by immunoblot; self-renewal assay; co-IP for Dclk1-ATM interaction\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with defined molecular pathway phenotype and Co-IP interaction data, single lab\",\n      \"pmids\": [\"27876863\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DCLK1 overexpression in pancreatic cancer cells drives >2-fold increase in invasion and drug resistance and increases KRAS activation, as measured by a RAS pull-down assay. Co-immunoprecipitation demonstrated DCLK1–KRAS interaction. High DCLK1 expression in TCGA PAAD correlates with activated PI3K/AKT/MTOR pathway signaling consistent with elevated KRAS activity.\",\n      \"method\": \"Stable lentiviral DCLK1-isoform2 overexpression; Matrigel invasion assay; RAS activation pull-down assay; co-immunoprecipitation; Everolimus/LY294002/ABT-199 drug resistance assays; KPC mouse model\",\n      \"journal\": \"Journal of oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KRAS activation pull-down + Co-IP, overexpression gain-of-function with multiple readouts, single lab\",\n      \"pmids\": [\"31467540\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DCLK1 binds and phosphorylates XRCC5 (Ku80), which in turn transcriptionally activates cyclooxygenase-2 (COX-2) expression and enhances prostaglandin E2 (PGE2) production, generating an inflammatory tumor microenvironment and driving aggressive behavior of colorectal cancer cells. This mechanism was identified by comprehensive proteomics/genomics analysis and validated functionally in CRC mouse models.\",\n      \"method\": \"Proteomics and genomics analyses to identify DCLK1 binding partners; Co-IP for DCLK1–XRCC5 interaction; in vitro kinase assay; COX-2/PGE2 functional measurements; CRC mouse models\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — substrate identified by proteomics and Co-IP, kinase activity on XRCC5, in vivo validation, single lab\",\n      \"pmids\": [\"35910805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DCLK1 influences small extracellular vesicle (sEV/exosome) biogenesis and cargo selection in a kinase-dependent manner in gastric cancer cells. sEVs from DCLK1-overexpressing cells promote migration of parental cells. Quantitative proteomics of sEVs identified enrichment of migratory/adhesion regulators (STRAP, CORO1B, BCAM, COL3A, CCN1). Treatment with DCLK1-IN-1 reversed increases in sEV size/concentration and kinase-dependent cargo selection of EV biogenesis proteins (KTN1, CHMP1A, MYO1G) and migration proteins.\",\n      \"method\": \"Stable DCLK1 overexpression; sEV isolation; quantitative proteomics of sEVs; DCLK1-IN-1 pharmacological inhibition; migration assay\",\n      \"journal\": \"Proteomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative proteomics with pharmacological kinase inhibition validation, single lab\",\n      \"pmids\": [\"33991177\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"KDM3A histone demethylase binds to the DCLK1 promoter and increases DCLK1 expression by removing H3K9me2 methylation marks. Knockdown of KDM3A in pancreatic cancer cells reduces DCLK1 levels; overexpression of KDM3A in non-cancerous HPNE cells increases DCLK1. This epigenetic regulation was confirmed by ChIP assay identifying KDM3A binding sites in the DCLK1 promoter.\",\n      \"method\": \"KDM3A knockdown and overexpression in pancreatic cell lines; ChIP assay for KDM3A binding at DCLK1 promoter; RNA sequencing; immunofluorescence co-localization; orthotopic tumor models\",\n      \"journal\": \"Gastroenterology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — ChIP identifies KDM3A binding at DCLK1 promoter, loss- and gain-of-function experiments, in vivo validation, multiple orthogonal methods\",\n      \"pmids\": [\"31442435\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Human colorectal cancers predominantly express a short DCLK1 isoform (DCLK1-S) from an alternate β-promoter located in Intron V of the DCLK1 gene, while normal colons express DCLK1-L from the 5'(α)-promoter. Activated NF-κBp65 binding to NF-κB cis-elements activates the β-promoter in cancer cells, whereas β-catenin/TCF4/LEF binding sites activate the α-promoter. This was confirmed by promoter-reporter and molecular biology approaches.\",\n      \"method\": \"In silico promoter analysis; promoter-reporter assays; molecular biology characterization of isoforms; NF-κBp65 and β-catenin functional studies; cohort analysis of isoform expression\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assays with defined transcription factor binding sites, multiple molecular biology methods, single lab\",\n      \"pmids\": [\"26447334\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"LEF1 (lymphoid enhancer-binding factor 1) directly binds the DCLK1-B promoter to transcriptionally activate DCLK1-B expression. Niclosamide blocks this interaction, reducing DCLK1-B expression. DCLK1-B depletion impairs cancer stemness, reduces survival, and sensitizes CRC to chemoradiation.\",\n      \"method\": \"Chromatin immunoprecipitation; promoter-reporter assays; siRNA knockdown of LEF1 and DCLK1-B; in vivo xenograft and AOM/DSS models\",\n      \"journal\": \"Clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP and reporter assay demonstrate LEF1 binding to DCLK1-B promoter, loss-of-function phenotype in vivo, single lab\",\n      \"pmids\": [\"30446587\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"miR-195 directly interacts with the Dclk1 mRNA 3'-UTR and inhibits DCLK1 translation. RNA-binding protein HuR competes with miR-195 for binding to Dclk1 mRNA and increases DCLK1 expression. Transgenic miR-195 overexpression in mice reduces DCLK1-positive tuft cells and increases vulnerability of the gut barrier.\",\n      \"method\": \"Luciferase reporter assay with Dclk1 3'-UTR; intestinal epithelial miR-195 transgenic mice; organoid culture; RNA pulldown/RIP for HuR-Dclk1 mRNA interaction\",\n      \"journal\": \"American journal of physiology. Cell physiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — luciferase 3'-UTR reporter validates direct miR-195 targeting, HuR competition validated, transgenic mouse phenotype confirms functional relevance, single lab\",\n      \"pmids\": [\"33788631\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DCLK1 promotes immune escape in colorectal cancer by upregulating CXCL1, which recruits MDSCs through CXCR2 to suppress CD8+ T cell activity. DCLK1-/- tumor cells (CRISPR/Cas9) lose tumorigenicity under immune surveillance. Overexpression of CXCL1 rescued in vivo tumor growth of DCLK1-/- cells.\",\n      \"method\": \"CRISPR/Cas9 DCLK1 knockout tumor cells; subcutaneous and orthotopic tumor transplant models; flow cytometry of tumor-infiltrating immune cells; MDSC sorting and T-cell co-culture; RNA sequencing; CXCL1 rescue experiment\",\n      \"journal\": \"Cellular and molecular gastroenterology and hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — CRISPR KO with in vivo rescue experiment, MDSC mechanistic pathway validated by sorting/co-culture, RNA-seq, multiple orthogonal methods\",\n      \"pmids\": [\"36309200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Dclk1+ cells are necessary for pancreatic regeneration following injury. In vivo, loss of Dclk1+ cells has detrimental effects after cerulein-induced pancreatitis. In vitro, Dclk1+ cells proliferate readily and sustain pancreatic organoid growth. In the context of oncogenic Kras, experimental pancreatitis converts Kras-mutant Dclk1+ cells into potent cancer-initiating cells.\",\n      \"method\": \"Genetic lineage tracing (Dclk1-CreER); cerulein-induced pancreatitis model; Dclk1+ cell ablation; in vitro organoid growth assay; Kras mutant mouse model\",\n      \"journal\": \"Cell stem cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic lineage tracing plus conditional cell ablation with defined regenerative and oncogenic phenotypes, multiple orthogonal in vivo and in vitro methods\",\n      \"pmids\": [\"27058937\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Dclk1 marks tumor stem cells (TSCs) rather than normal stem cells in the intestine of ApcMin/+ mice. Lineage tracing showed that Dclk1+ cells continuously produce tumor progeny in polyps. Specific ablation of Dclk1-positive TSCs resulted in marked regression of polyps without apparent damage to the normal intestine.\",\n      \"method\": \"Genetic lineage tracing (Dclk1-CreER;Rosa26-reporter); Dclk1+ cell-specific ablation in ApcMin/+ mice; polyp quantification; histological analysis of normal intestine\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — lineage tracing plus conditional cell ablation in genetic cancer model, clear TSC-specific vs. normal stem cell distinction established in vivo\",\n      \"pmids\": [\"23202126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Dclk1 deletion in intestinal epithelial cells (VillinCre;Dclk1flox/flox) results in failure to maintain tight junctions after radiation injury and early lethality (~day 5 vs. day 10 in controls), demonstrating a functional role for Dclk1 in epithelial restoration after genotoxic insult. Widespread gene expression changes were detected in isolated intestinal epithelia during homeostasis in Dclk1-deficient mice.\",\n      \"method\": \"Conditional intestinal Dclk1 knockout mice; total body irradiation; survival analysis; tight junction assessment; global gene expression profiling\",\n      \"journal\": \"Stem cells (Dayton, Ohio)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with specific phenotypic readout (tight junctions, survival), single lab\",\n      \"pmids\": [\"24123696\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"DCLK1 overexpression in pancreatic neuroendocrine tumor (PNET) cells induces EMT-related gene signatures including upregulation of Slug/SNAI2, N-Cadherin, and Vimentin. QGP1-DCLK1 cells showed increased migration, formed larger xenograft tumors, and activated p-FAK (Tyr925), p-ERK1/2, p-AKT, Paxillin, and Cyclin D1. Pharmacological inhibition or knockdown of DCLK1 abolished expression of these molecules.\",\n      \"method\": \"DCLK1 overexpression in QGP1 cells; xenograft tumor model; wound-healing migration assay; immunoblot for FAK/ERK/AKT; pharmacological and siRNA inhibition\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function overexpression with pharmacological and siRNA inhibition confirming pathway activation, in vivo validation, single lab\",\n      \"pmids\": [\"28179411\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Thrombin activates DCLK1, which then activates RhoA and YAP in lung epithelial cells. YAP undergoes dephosphorylation at Ser127 and translocates to the nucleus. YAP and p65 are recruited to the NF-κB site of the IL-8/CXCL8 promoter, enhancing IL-8 expression. DCLK1 siRNA inhibited RhoA and YAP activation and blocked YAP/p65 recruitment to the IL-8 promoter. DCLK1/RhoA/YAP activation was ERK-dependent (inhibited by U0126).\",\n      \"method\": \"siRNA knockdown of DCLK1/RhoA/YAP; DCLK1 inhibitor LRRK2-IN-1; κB-luciferase reporter assay; ChIP assay for YAP/p65 at IL-8 promoter; Western blot for pathway components; in vivo asthma model\",\n      \"journal\": \"Journal of biomedical science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP validates pathway mechanism, multiple siRNA targets, luciferase reporter, single lab\",\n      \"pmids\": [\"36369000\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"DCLK1 interacts with CCAR1 (cell cycle and apoptosis regulator 1) through its C-terminal domain and phosphorylates CCAR1 at Ser343, which is essential for CCAR1 stabilization. DCLK1 positively regulates β-catenin signaling via CCAR1, which maintains cancer stemness and 5-FU resistance in colorectal cancer cells.\",\n      \"method\": \"Co-immunoprecipitation for DCLK1–CCAR1 interaction; in vitro kinase assay for CCAR1 phosphorylation at Ser343; DCLK1/CCAR1 siRNA knockdown; β-catenin pathway analysis; 5-FU resistant cell line models; in vivo xenograft assay\",\n      \"journal\": \"Clinical and translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identifies binding partner, kinase assay demonstrates phosphorylation at specific site, downstream pathway validated, single lab\",\n      \"pmids\": [\"35522902\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Knockdown of Dclk1 in ApcMin/+ mice attenuates intestinal adenomas and adenocarcinoma, decreases pro-survival signaling (including NF-κB/RELA and NOTCH1 pathways), reduces pluripotency factors, and impairs self-renewal. Knocking down RELA, NOTCH1 signaling, and DCLK1 in colon cancer cells in vitro reduces tumor cell self-renewal and survival, establishing Dclk1 as a regulator of pro-survival and stemness signaling in intestinal tumors.\",\n      \"method\": \"Dclk1 knockdown in ApcMin/+ mice; siRNA knockdown of RELA and NOTCH1 in colon cancer cells; FACS; IHC; Western blot; clonogenic self-renewal assays\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KD with pathway-specific siRNA epistasis in vitro, multiple readouts, single lab\",\n      \"pmids\": [\"28148261\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"DCLK1-isoform2 overexpression in pancreatic cancer cells causes polarization of M1-macrophages toward an immunosuppressive M2 phenotype via secreted chemokines/cytokines. DCLK1-isoform2-educated M2-macrophages enhance parental PDAC cell migration, invasion, and self-renewal, and inhibit CD8+ T-cell proliferation and granzyme-B activation. Inhibition of DCLK1 in an organoid co-culture system enhanced CD8+ T-cell activation and organoid death.\",\n      \"method\": \"DCLK1-isoform2 stable overexpression; macrophage polarization assay; CD8+ T-cell co-culture; organoid co-culture with DCLK1 inhibition; KPCY autochthonous mouse model immunostaining\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with macrophage co-culture and T-cell functional assays, in vivo mouse model validation, single lab\",\n      \"pmids\": [\"32371580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"DCLK1 overexpression promotes EMT and activates the ERK MAPK pathway in breast cancer cells, leading to enhanced expression of MT1-MMP. CRISPR/Cas9-mediated DCLK1 knockout reduces EMT markers (decreases ZO-1 loss, reduces ZEB1 and Vimentin), and reduces migration and invasion. This identifies ERK MAPK/MT1-MMP as a downstream pathway of DCLK1 in breast cancer metastasis.\",\n      \"method\": \"CRISPR/Cas9 DCLK1 knockout; stable DCLK1 overexpression; migration/invasion assays; immunoblot for EMT and ERK MAPK pathway markers; MT1-MMP expression analysis\",\n      \"journal\": \"BioMed research international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR KO plus overexpression with pathway analysis, single lab\",\n      \"pmids\": [\"31223610\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"DCLK1 is a bifunctional microtubule-associated serine/threonine kinase: its N-terminal doublecortin-like domain binds and polymerizes microtubules (independent of kinase activity), while its C-terminal kinase domain—held in autoinhibition by a C-terminal autoinhibitory domain (AID) that blocks the ATP-binding site—is activated by Ca²⁺-dependent binding of HPCAL1 to the AID; in neurons DCLK1 phosphorylates MAP7D1-Ser315 to promote axon elongation and labels dendritic microtubules to guide KIF1-dependent cargo trafficking; in cancer cells DCLK1 kinase activity drives EMT and stemness via multiple miRNA-dependent (let-7a, miR-200, miR-145) and kinase-dependent mechanisms including phosphorylation of IKKβ-S177/181 (activating NF-κB in macrophages), XRCC5/Ku80 (activating COX-2/PGE2), and CCAR1-Ser343 (stabilizing β-catenin signaling), and promotes immune evasion through CXCL1-mediated MDSC recruitment and M2 macrophage polarization; DCLK1 expression is epigenetically regulated by KDM3A-mediated H3K9 demethylation and by NF-κB-driven alternate promoter usage in cancer cells.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"DCLK1 is a bifunctional microtubule-associated serine/threonine kinase whose two activities are structurally and functionally separable: an N-terminal doublecortin-like domain binds purified tubulin and drives microtubule polymerization and bundling independent of catalytic activity, while a distinct C-terminal kinase domain phosphorylates protein substrates [#0]. The kinase domain is held in an autoinhibited conformation by a C-terminal autoinhibitory domain (AID) that occludes the ATP-binding site; truncation of the C-terminus elevates activity ~10-fold, and Ca\\u00b2\\u207a-dependent binding of the neuronal calcium sensor HPCAL1 to the AID releases this autoinhibition, while cancer-associated AID mutations constitutively upregulate kinase activity [#3, #6]. In the nervous system DCLK1 decorates a subset of dendritic microtubules to direct KIF1/kinesin-3-dependent dense-core vesicle trafficking and dendrite development, and phosphorylates MAP7D1 at Ser315 to promote cortical axon elongation [#1, #2]. Beyond neurons, DCLK1 marks regenerative and tumor-initiating cell populations: Dclk1+ tuft/stem cells support intestinal and pancreatic epithelial restoration after injury and, in oncogenic Kras or Apc-mutant contexts, behave as cancer-initiating/tumor stem cells whose ablation regresses tumors without harming normal tissue [#24, #25, #14]. In cancer its kinase activity drives EMT, stemness, and an inflammatory microenvironment through defined substrates and partners\\u2014phosphorylating IKK\\u03b2 at S177/181 to activate NF-\\u03baB in macrophages [#8], XRCC5/Ku80 to transcriptionally induce COX-2/PGE2 [#17], and CCAR1 at Ser343 to stabilize \\u03b2-catenin signaling [#29]\\u2014and through repression of tumor-suppressive miRNA programs (let-7a, miR-200, miR-145) that control pluripotency factors, KRAS, and EMT transcription factors [#10, #11, #12]. DCLK1 further promotes immune evasion via CXCL1-driven MDSC recruitment and M2 macrophage polarization [#23, #31]. DCLK1 expression itself is controlled epigenetically by KDM3A-mediated H3K9 demethylation at its promoter and by a switch to an alternate NF-\\u03baB/LEF1-driven \\u03b2-promoter producing a short isoform in cancer [#19, #20, #21].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established that DCLK1 is a dual-function protein\\u2014a microtubule-polymerizing MAP and an active kinase\\u2014whose two activities are genetically separable, framing all later mechanistic work.\",\n      \"evidence\": \"In vitro microtubule polymerization with purified protein, kinase assays on MBP, and kinase-dead mutagenesis in cells\",\n      \"pmids\": [\"11124993\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological kinase substrates not identified\", \"Regulation of the two activities in vivo unaddressed\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Defined the C-terminus as an autoinhibitory module by showing its removal increases kinase activity ~10-fold, and that splice variants differ in subcellular localization.\",\n      \"evidence\": \"In vitro kinase assays on CaMK substrates with C-terminal truncation mutants and immunofluorescence\",\n      \"pmids\": [\"14741399\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of autoinhibition not resolved\", \"Physiological trigger for de-repression unknown\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified neuronal roles for DCLK1: MAP7D1-Ser315 phosphorylation drives axon elongation and dendritic-microtubule labeling directs KIF1-dependent cargo, linking kinase and MAP functions to neuronal morphogenesis.\",\n      \"evidence\": \"Phosphoproteomic substrate ID with phosphomimetic rescue; kinesin family-wide screen and knockdown in neurons\",\n      \"pmids\": [\"27503845\", \"26758546\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How DCLK1 selects dendritic microtubule subsets is unknown\", \"Whether KIF1 guidance requires DCLK1 kinase activity not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Resolved the autoinhibition mechanism structurally and identified its physiological release switch, showing the AID blocks the ATP site and HPCAL1 binds the AID in a Ca\\u00b2\\u207a-dependent manner to activate the kinase.\",\n      \"evidence\": \"Crystal structure of the autoinhibited kinase domain plus HPCAL1\\u2013AID binding and Ca\\u00b2\\u207a-activation assays; inhibitor co-crystals\",\n      \"pmids\": [\"34977835\", \"34545159\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether HPCAL1 activation operates outside neurons unknown\", \"Cellular contexts that supply the Ca\\u00b2\\u207a signal not mapped\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Demonstrated an in vivo developmental role outside the nervous system, placing DCLK1 as a Runx2 antagonist controlling osteoblast differentiation and bone mass.\",\n      \"evidence\": \"Dclk1-null mice with bone phenotyping and Runx2+/-;Dclk1-/- double-mutant epistasis\",\n      \"pmids\": [\"23918955\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of Runx2 antagonism not defined\", \"Whether kinase activity is required unaddressed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established Dclk1+ cells as injury-responsive regenerative/cancer-initiating populations through lineage tracing and ablation, distinguishing tumor stem cells from normal stem cells.\",\n      \"evidence\": \"Dclk1-CreER lineage tracing and conditional cell ablation in pancreatitis/Kras and ApcMin/+ models\",\n      \"pmids\": [\"27058937\", \"23202126\", \"24123696\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-intrinsic molecular program conferring stemness not fully defined\", \"Relationship between marker status and DCLK1 enzymatic function unclear\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Linked Dclk1 in tuft cells to injury-induced ATM activation and COX-2/PGE2 production driving epithelial proliferation, establishing a DNA-damage/inflammation axis.\",\n      \"evidence\": \"Conditional intestinal Dclk1 knockout, irradiation, Co-IP for Dclk1\\u2013ATM, and PGE2 organoid rescue\",\n      \"pmids\": [\"27876863\", \"30478383\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether Dclk1\\u2013ATM interaction is direct/kinase-dependent not resolved\", \"Paracrine signal identity incompletely defined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Positioned DCLK1 as a master repressor of tumor-suppressive miRNA networks (let-7a, miR-200, miR-145) controlling pluripotency factors, KRAS, and EMT transcription factors.\",\n      \"evidence\": \"siRNA knockdown with luciferase reporters and RT-PCR in colorectal/pancreatic cancer cells and xenografts\",\n      \"pmids\": [\"19445940\", \"21285251\", \"24040120\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism by which DCLK1 controls miRNA biogenesis unknown\", \"Whether kinase activity is required not established\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified direct kinase substrates and binding partners driving cancer inflammation and stemness: IKK\\u03b2 (NF-\\u03baB), XRCC5/Ku80 (COX-2/PGE2), and CCAR1 (\\u03b2-catenin stabilization).\",\n      \"evidence\": \"Co-IP/LC-MS-MS partner identification, in vitro kinase assays on defined sites, and conditional KO/inhibition in vivo\",\n      \"pmids\": [\"36896602\", \"35910805\", \"35522902\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Substrate specificity determinants not mapped\", \"Relative contribution of each substrate in vivo unclear\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined DCLK1's role in immune evasion via CXCL1-mediated MDSC recruitment and M2 macrophage polarization suppressing CD8+ T-cell activity.\",\n      \"evidence\": \"CRISPR DCLK1 knockout with in vivo CXCL1 rescue, MDSC sorting/co-culture, and macrophage polarization assays\",\n      \"pmids\": [\"36309200\", \"32371580\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism linking DCLK1 kinase activity to CXCL1 induction unresolved\", \"Whether MDSC and M2 axes are independent not determined\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Connected DCLK1 to additional cancer effectors: kinase-dependent extracellular-vesicle cargo selection, KRAS activation, and ERK/RhoA/YAP signaling driving EMT.\",\n      \"evidence\": \"Overexpression/knockout with sEV proteomics, RAS pull-down and Co-IP, ChIP, and pathway immunoblots across pancreatic/breast/lung models\",\n      \"pmids\": [\"33991177\", \"31467540\", \"32755567\", \"31223610\", \"36369000\", \"28179411\", \"28148261\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct versus indirect engagement of KRAS/RhoA/YAP not fully separated\", \"CDK11 as a substrate remains preliminary\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Explained how DCLK1 expression is itself reprogrammed in cancer: KDM3A H3K9 demethylation activates its promoter and an NF-\\u03baB/LEF1-driven alternate \\u03b2-promoter produces a short oncogenic isoform.\",\n      \"evidence\": \"ChIP, promoter-reporter assays, gain/loss-of-function, and in vivo tumor models; miR-195/HuR 3'-UTR translational control\",\n      \"pmids\": [\"31442435\", \"26447334\", \"30446587\", \"33788631\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional differences between long and short isoforms not fully resolved\", \"Upstream signals selecting promoter usage incompletely defined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how DCLK1's MAP versus kinase functions and its long versus short isoforms are partitioned to dictate context-specific outcomes across neurons, epithelial regeneration, and the many cancer signaling axes attributed to it.\",\n      \"evidence\": \"No single study reconciles the activity/isoform partitioning across tissues\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model linking isoform expression to specific substrate engagement\", \"Whether neuronal HPCAL1/Ca\\u00b2\\u207a activation operates in cancer cells untested\", \"Which cancer phenotypes require catalytic activity versus MAP function not systematically dissected\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 6, 8, 17, 29]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 8, 17, 29]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005856\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 11, 23, 25]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 16, 28, 29]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [8, 23, 31]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [1, 2, 7]},\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [19, 20, 21]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"HPCAL1\", \"MAP7D1\", \"IKBKB\", \"XRCC5\", \"CCAR1\", \"ATM\", \"KRAS\", \"CDK11\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}